Development of novel agents for idiopathic pulmonary fibrosis: Progress in target selection and clinical trial design

Chest

Volumn 148, Issue 4, 2015, Pages 1083-1092

  O'Riordan, Thomas G ^a   Smith, Victoria ^b   Raghu, Ganesh ^c  

^a GILEAD SCIENCES INC   (United States)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHAVBETA6 INTEGRIN; AMBRISENTAN; BETA CATENIN; BIOLOGICAL MARKER; BLEOMYCIN; DIPHTHERIA TOXIN; FIBROBLAST GROWTH FACTOR RECEPTOR; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SILDENAFIL; SILICON DIOXIDE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR; WNT PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FIBROSING ALVEOLITIS; FOOD AND DRUG ADMINISTRATION; FORCED VITAL CAPACITY; GENE EXPRESSION REGULATION; HELPER CELL; HUMAN; KNOCKOUT MOUSE; LUNG FIBROBLAST; LUNG FUNCTION; MOLECULAR PATHOLOGY; MOUSE MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; UNITED STATES; UPREGULATION; DRUG DEVELOPMENT; IDIOPATHIC PULMONARY FIBROSIS; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS;

EID: 84938334044     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-3218     Document Type: Article

References (78)

1. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.
2. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760-1769.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370 (22): 2083-2092.
4. Richeldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370 (22): 2071-2082.
5. Raghu G, Brown KK, Bradford WZ, et al; Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350 (2): 125-133.
6. King TE Jr, Albera C, Bradford WZ, et al; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374 (9685): 222-228.
7. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184 (1): 92-99.
8. Raghu G, Behr J, Brown KK, et al; the ARTEMIS-IPF investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158 (9): 641-649.
9. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013; 5 (167): 167sr1.
10. Lota HK, Wells AU. The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother. 2013; 14 (1): 79-89.
11. Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013; 64 : 265-276.
12. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012; 380 (9842): 680-688.
13. Boucher RC. Idiopathic pulmonary fibrosis-a sticky business. N Engl J Med. 2011; 364 (16): 1560-1561.
14. Tayek JA, Kalantar-Zadeh K. The extinguished BEACON of bardoxolone: not a Monday morning quarterback story. Am J Nephrol. 2013; 37 (3): 208-211.
15. Kulkarni AA, Thatcher TH, Hsiao HM, et al. The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis. PLoS ONE. 2013; 8 (5): e63798.
16. Hecker L, Cheng J, Thannickal VJ. Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci. 2012; 69 (14): 2365-2371.
17. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G; Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370 (22): 2093-2101.
18. Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin a (v) b 6, an activator of latent transforming growth factor- b, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008; 177 (1): 82-90.
19. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90 (2): 770-774.
20. Moshai EF, Wémeau-Stervinou L, Cigna N, et al. Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol. 2014; 51 (1): 11-25.
21. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366 (23): 2171-2179.
22. Henderson WR Jr, Chi EY, Ye X, et al. Inhibition of Wnt/betacatenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010; 107 (32): 14309-14314.
23. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366 (21): 1968-1977.
24. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365 (12): 1079-1087.
25. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007; 29 (5): 976-985.
26. Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol. 2012; 46 (3): 355-364.
27. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013 ;5(205):205ra136.
28. Naik PK, Bozyk PD, Bentley JK, et al; COMET Investigators. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303 (12): L1046-L1056.
29. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE. 2010; 5 (3): e9683.
30. Vittal R, Mickler EA, Fisher AJ, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF- b and associated transcripts in pulmonary fibrosis. PLoS ONE. 2013; 8 (10): e76451.
31. Marinkovic A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate IPF fibroblasts. Am J Respir Cell Mol Biol. 2013; 48 (4): 422-430.
32. Klingberg F, Chow ML, Koehler A, et al. Prestress in the extracellular matrix sensitizes latent TGF- b 1 for activation. J Cell Biol. 2014; 207 (2): 283-297.
33. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010; 16 (9): 1009-1017.
34. Aono Y, Ledford JG, Mukherjee S, et al. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med. 2012; 185 (5): 525-536.
35. Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013; 123 (3): 1096-1108.
36. Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011; 108 (52): E1475-E1483.
37. KönigshoffM, Saglani S, Marsland BJ, Eickelberg O. Rebuilding a diseased lung: repair and regeneration. Eur Respir J. 2013; 41 (3): 497-499.
38. Brouwer KM, Hoogenkamp HR, Daamen WF, van Kuppevelt TH. Regenerative medicine for the respiratory system. Am J Respir Crit Care Med. 2013; 187 (5): 468-475.
39. Kaminski N, Rosas IO. Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis. Can we identify the right target genes? Proc Am Thorac Soc J. 2006;3(4): 339-344.
40. Montesi SB, Mathai SK, Brenner LN, et al. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med. 2014; 14 (1): 5.
41. Davies ER, Haitchi HM, Thatcher TH, et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 46 (5): 687-694.
42. Murray LA, Zhang H, Oak SR, et al. Targeting IL-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID IPF model. Am J Respir Cell Mol Biol. 2014; 50 (5): 985-994.
43. B Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013; 49 (2): 167-179.
44. Henderson WR, Ye X, Tien Y, Wright CD. Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model. Poster presented at: European Respiratory Society Congress; September 2010; Barcelona, Spain.
45. Peng R, Sridhar S, Tyagi G, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS ONE. 2013; 8 (4): e59348.
46. Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 47 (5): 566-574.
47. Bonniaud P, Martin G, Margetts PJ, et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs. Am J Respir Cell Mol Biol. 2004; 31 (5): 510-516.
48. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovectormediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997; 100 (4): 768-776.
49. Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 181 (3): 254-263.
50. Langley RJ, Mishra NC, Peña-Philippides JC, Hutt JA, Sopori ML. Granuloma formation induced by low-dose chronic silica inhalation is associated with an anti-apoptotic response in Lewis rats. J Toxicol Environ Health A. 2010; 73 (10): 669-683.
51. Roman J, Brown KK, Olson A, Corcoran BM, Williams KJ; ATS Comparative Biology of Lung Fibrosis Working Group. An official American Thoracic Society workshop report: comparative pathobiology of fibrosing lung disorders in humans and domestic animals. Ann Am Thorac Soc. 2013; 10 (6): S224-S229.
52. Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther. 1989; 46 (1): 63-77.
53. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184 (4): 459-466.
54. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013 ;22(128):148-152.
55. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008; 246 (3): 935-940.
56. De Backer J, Vos W, Smaldone GC, Skaria S, Condos, R. Disease progression in IPF assessed using pulmonary function tests and functional respiratory imaging (FRI)-a pilot study. Am J Respir Crit Care Med. 2014 ;189:A2383.
57. Kaushik SS, Heacock T, Freeman M, et al. Hyperpolarized 129Xe spectroscopy as a biomarker for gas-transfer impairment in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014 ;189:A5422.
58. John AE, Luckett JC, Tatler AL, et al. Preclinical SPECT/CT imaging of a v b 6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med. 2013; 54 (12): 2146-2152.
59. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014; 43 (5): 1430-1438.
60. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012; 31 (25): 2973-2984.
61. Liu S, Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014; 40 (7): 883-891.
62. Diaz KT, Skaria S, Harris K, et al. Delivery and safety of inhaled interferon-g in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2012; 25 (2): 79-87.
63. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor- b 1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012; 185 (5): 537-546.
64. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015; 191 (3): 252-254.
65. Fleming TR. Current issues in non-inferiority trials. S tat Med. 2008; 27 (3): 317-332.
66. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012; 185 (10): 1044-1048.
67. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012; 67 (11): 938-940.
68. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib . N Engl J Med. 2015; 372 (13): 1189-1191.
69. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013; 14 : 73.
70. Raghu G, Lynch D, Godwin JD, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014; 2 (4): 277-284.
71. Costabel U, Inoue Y, Richeldi L, et al. Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS trials. Oral presentation at: ERS International Congress, September 8, 2014; Munich, Germany.
72. Ley B, Bradford WZ, Weycker D, VittinghoffE, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 ;45:1374-1381.
73. Kim YJ, Shin SH, Park JW, et al. Annual change in pulmonary function and clinical characteristics of combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis: over a 3-year follow-up. Tuberc Respir Dis (Seoul). 2014; 77 (1): 18-23.
74. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J; MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42 (6): 1622-1632.
75. Krowka MJ, Ahmad S, de Andrade JA, et al. A randomized, doubleblind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. Chest. 2007; 132 (4-MeetingAbstracts):586.
76. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363 (7): 620-628.
77. Han MK, Bach DS, Hagan PG, et al; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013; 143 (6): 1699-1708.
78. Molyneaux L, Lukey PT, Fraser UH, Renzoni EA, Wells A, Maher TM. Daily hand-held spirometry for the monitoring of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185:A4579.